Trial reportHaematologica2017
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis.BMJ open · 2023Pooled it
- The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.Pharmacology & therapeutics · 2020Pooled it
- Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.European journal of haematology · 2020Trial
- Trial
- Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil.Cancers · 2024Article
- Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.Annals of hematology · 2023Article
- Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database.PloS one · 2023Article
- The emerging therapeutic landscape of relapsed/refractory multiple myeloma.Annals of hematology · 2023Review
- [Expert consensus on the prevention and treatment of multiple myeloma related venous thromboembolism in China (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives.Pharmaceutics · 2022Review
- The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.Biomarker research · 2022Review
- Article
- Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.Cancer research · 2020Article
- Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.The Journal of molecular diagnostics : JMD · 2020Article
- c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.European journal of haematology · 2020Article
- Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.Annals of hematology · 2020Observational
- Efficacy of ixazomib for the treatment of relapsed/refractory multiple myeloma: A protocol of systematic review and meta-analysis.Medicine · 2020Article
- How I treat a refractory myeloma patient who is not eligible for a clinical trial.Hematology. American Society of Hematology. Education Program · 2019Article
- Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.Pathology oncology research : POR · 2019Article
- A Practical Review of Proteasome Pharmacology.Pharmacological reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone (ixazomib-Rd)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.